Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants
Rhea-AI Filing Summary
Moleculin Biotech, Inc. reports that Chief Science Officer Donald H. Picker purchased 173,333 shares of common stock and Series I Warrants to purchase 519,999 shares on August 3, 2026, in a public offering at a combined purchase price of $0.75 per one share and three warrants. Following these transactions, he directly holds 174,086 common shares and 539,595 Series I Warrants.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 173,333 shares
Net Buy
2 txns
Insider
PICKER DONALD H
Role
Chief Science Officer
Bought
693,332 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series I Warrants F1 | 519,999 | -- | -- |
| Purchase | Common Stock F1 | 173,333 | -- | -- |
Holdings After Transaction:
Series I Warrants — 539,595 shares (Direct);
Common Stock — 174,086 shares (Direct)
Footnotes (1)
- F1. On August 3, 2026, The reporting person acquired 173,333 shares of common stock and Series I warrants to purchase 519,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.
Key Figures
Common shares purchased: 173,333 shares
Series I Warrants purchased: 519,999 warrants
Combined purchase price: $0.75
+2 more
5 metrics
Common shares purchased
173,333 shares
Purchased on August 3, 2026 in a public offering
Series I Warrants purchased
519,999 warrants
Acquired on August 3, 2026 alongside common shares in a public offering
Combined purchase price
$0.75
Per one share of common stock and three accompanying warrants in a public offering
Common shares held after
174,086 shares
Directly owned by Donald H. Picker after the August 3, 2026 transactions
Series I Warrants held after
539,595 warrants
Directly owned by Donald H. Picker after the August 3, 2026 transactions
Key Terms
Series I Warrants, combined purchase price, public offering
3 terms
Series I Warrants financial
"acquired 173,333 shares of common stock and Series I warrants to purchase 519,999 shares"
combined purchase price financial
"at a combined purchase price of $0.75 per one share of common stock"
public offering financial
"three accompanying warrants in a public offering"
A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Moleculin Biotech (MBRX) report for Donald H. Picker?
Moleculin Biotech reported that Chief Science Officer Donald H. Picker bought 173,333 common shares and Series I Warrants for 519,999 shares on August 3, 2026, in a public offering. The filing shows these are directly owned holdings.
What warrants did Moleculin Biotech (MBRX) CSO acquire in the August 3, 2026 transaction?
Donald H. Picker acquired Series I Warrants to purchase 519,999 shares of Moleculin Biotech common stock. These warrants were acquired together with common shares as part of a public offering at a combined price per share and accompanying warrants.
At what price did Donald H. Picker buy Moleculin Biotech (MBRX) securities?
Donald H. Picker bought the securities at a combined purchase price of $0.75 per one share of common stock and three accompanying Series I Warrants. This combined pricing applied within a public offering structure described in the Form 4 footnote.
Was Donald H. Picker’s Moleculin Biotech (MBRX) purchase under a Rule 10b5-1 plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, and no footnote references a trading plan. The transactions are reported simply as open market or private purchases linked to a public offering.